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Introduction
In her review on hormone replacement therapy and breast
cancer, published in the present issue of Breast Cancer
Research [1], Catherine Schairer concludes that studies
“suggest, for the most part, that estrogen–progestin
replacement therapy has a more adverse effect on breast
cancer risk than estrogen replacement therapy”. This rela-
tively tentative conclusion has now been amply confirmed
by the recent publication of the results of the Women’s
Health Initiative (WHI) trial [2] in the case of the most
commonly prescribed estrogen–progestin replacement
therapy (EPRT) regimen. The WHI large, randomized trial
compared continuous combined EPRT (conjugated
equine estrogen at 0.625 mg/day with medroxyproges-
terone acetate at 2.5 mg/day) with placebo and found
that, after a mean duration of use of 5.2 years, this EPRT
regimen increased the rate of breast cancer by 26%. This
is not a small increase; if all postmenopausal women used
this regimen for 5 years then, during the 5 years of use,
every four current breast cancer cases would become five.
Epidemiological studies suggest that there would be
further excess cases extending possibly for many years
after the EPRT was stopped.
Minimizing progestin exposure
As noted by Schairer, it was predicted some 14 years
ago, based on the epidemiology and biology of breast
cancer, that EPRT would be more harmful to the breast
than estrogen replacement therapy [3,4]. An epidemio-
logic study from Scandinavia published in 1992 [5] sup-
ported this view and, as remarked on in the WHI report,
the WHI results are completely compatible with the most
definitive epidemiological studies.
Why was the epidemiological evidence on the higher risk
from EPRT effectively ignored by prescribers and regula-
tory authorities for so long? In a situation of admittedly
incomplete evidence, should we not have acted as if
EPRT quite possibly increased breast cancer risk more
than estrogen replacement therapy? If this possibility had
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been taken seriously, we would have had an aggressive
scientific effort to find ways to deliver progestins to the
endometrium (the whole point of delivering progestins) in
such a way as to minimize exposure to the breast. A direct
endometrial route of administration with minimal progestin
exposure to the breast was shown to be possible as early
as 1991 [6], and this has been confirmed in a recent
study [7]. If this is unacceptable to a woman, then a
vaginal route of administration shows great promise [8,9].
If this is also unacceptable, then giving progestins by
mouth (or transdermally) for 10–12 days every
3–4 months should provide satisfactory protection to the
endometrium if the estrogen dose is kept to no more than
standard-dose conjugated equine estrogen [10–12].
Conclusion
Schairer [1] and the WHI report [2] note that many ques-
tions remain to be answered regarding the breast cancer
risk from EPRT. In particular, what are the risks associated
with the many different regimens of EPRT that have been
licensed by the regulatory authorities? These regimens
cover transdermal delivery, the use of different estrogens
and progestins, and quite different sequences of delivery
of the progestins. Epidemiological breast cancer
case–control studies cannot answer all these questions in
the right timeframe (i.e. before many tens of thousands of
women have taken the regimens) and clinical trials with
breast cancer as the outcome are not going to be per-
formed to cover all the regimens available. It is therefore
incumbent on us to agree that some intermediate marker
of breast cancer risk must be used to show the probable
effect of a regimen and then, if this shows that the regimen
affects the intermediate marker in a manner to suggest
increased breast cancer, that we act accordingly. We
should in fact be prepared to act as if the effect on the
marker is a quantitative guide to the probable effect on
breast cancer risk.
There is considerable evidence in support of using
changes in mammographic densities as such a marker
[13]. A large, randomized trial with changes in mammo-
graphic density as the endpoint has already shown that
the usual sequential EPRT regimen with conjugated
equine estrogen and medroxyprogesterone acetate is
likely to increase breast cancer risk as much as the con-
tinuous combined regimen used in the WHI trial, and
that replacing medroxyprogesterone acetate with
micronized progesterone does not significantly alter the
added risk. Regulatory authorities need to require such
studies on all current regimens so that women can have
an evidence-based guide to the probable effects of dif-
ferent regimens. We should not allow regimens that are
not covered by the current epidemiological and WHI evi-
dence to be presented in such a way as to suggest that
they may not increase breast cancer risk without evi-
dence of this type.
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